Lockheed Martin vs. Northrop Grumman: Who's Currently the Better Play?

Lockheed Martin reported a $193.6B backlog as of Dec. 31, 2025, won a >$1B TRKT3 space-vehicle contract and a $233M IRST21 Block II award, with F-35 contributing ~27% of 2025 sales and Aeronautics sales up 6.4% YoY in Q4. Northrop Grumman holds a $95.68B backlog and expects to recognize ~35% of it in the next 12 months and ~60% in 24 months, positioning steady organic growth from multibillion-dollar defense opportunities. Valuation and estimates favor LMT: forward P/S 1.85x vs NOC 2.28x, Zacks 2026 EPS estimate change +1.29% for LMT vs -2.08% for NOC, long-term EPS growth 18.57% vs 4.8%, and six-month price performance +33.2% (LMT) vs +24% (NOC); both carry a Zacks Rank #3 (Hold).

Analysis

The market is treating both primes as direct plays on geopolitical premium, but the second‑order winner will be the firm that converts program wins into steady free cash flow rather than just headline backlog growth. Lockheed’s platform model should produce steadier margin conversion and predictable capex phasing, whereas Northrop’s program mix—heavier on multi‑year development and classified ISR—creates lumpy revenue and more volatile near‑term cash conversion. Supply‑chain bottlenecks (composites, avionics, rad-hard semis) and launch cadence for space vehicles are the operational levers that will determine which business actually delivers the booked dollars to the P&L over the next 12–24 months.

Key catalysts are discrete and timeable: DoD budget appropriations and major FMS approvals will move order timing within days–weeks, while program maturations and production ramps will drive material EPS/cash flow differences over 6–24 months. Tail risks are asymmetric—political/appropriations shocks or program technical overruns can compress multiples quickly; conversely, accelerated allied buys or a surge in missile‑defense funding could compress payback to under 12 months. Monitor book‑to‑bill, change orders, and monthly production rates rather than backlog headline numbers to separate durable growth from timing noise.

The consensus appears to underweight short‑to‑medium term working capital swings and overweights headline backlog as a valuation driver. That makes a relative trade attractive: buy the name whose backlog converts with fewer working capital drains and sell the name with longer R&D and development outlays. Watch margin guidance and cash conversion in the next two quarterly reports—those two datapoints will be the clearest differentiator of which multiple is justified over the next 12 months.

Key Decisions for Investors

• Pair trade (12‑month): Long LMT equity vs short NOC equity, equal dollar exposure. Target 10% relative outperformance in 12 months; stop if relative spread widens against position by 5%. Rationale: capture valuation/FCF conversion gap while hedging broad defense beta.
• Directional options (9–12 months): Buy LMT 12‑month call spread (buy ATM call / sell +15% OTM call) sized at 2–3% portfolio risk. Expect ~2:1 upside if multiple expands on continued production momentum; limited premium outlay caps downside.
• Tail hedge on budget/award risk (6 months): Buy NOC 6‑month 10–15% OTM puts sized to cover 25–30% of notional exposure to NOC. Cost should be ~0.5–1.0% of notional; payoff asymmetric if DoD funding or program awards miss expectations.
• Supply‑chain arbitrage (6–18 months): Overweight select high‑quality subcontractors (e.g., avionics/composites suppliers) with visible order flow and neutral balance sheets. These names will capture margin if primes face working capital strain; target 15–25% upside on production ramps, stop at 10% adverse move.